Pharmacy billing and revenue cycle, 50-state coverage.

CMS redefined the Part D negotiated price as the lowest possible reimbursement a network pharmacy will receive, in total, for a drug. The definition was finalised in the Contract Year 2023 Medicare Advantage and Part D final rule at 87 FR 27704, published May 9, 2022, codified at 42 CFR 423.100, and applicable from January 1, 2024. In practice the maximum negative adjustment now lands at the point of sale instead of arriving as a retroactive recovery months later. What did not change is the pressure. The pharmacy still has to measure realised reimbursement against the contracted effective rate across the book, because the concession moved in time rather than in size.

Not yet. The CMS Interoperability and Prior Authorization final rule at 89 FR 8758 requires impacted payers to decide standard requests within 7 calendar days and expedited requests within 72 hours from January 1, 2026, and it explicitly excludes drugs, on the reasoning that the standards and processes for drug authorisations differ from those for medical items and services. Drugs run on their own clocks instead. A Medicaid response on a covered outpatient drug prior authorization is required within 24 hours under section 1927(d)(5) of the Social Security Act, and Medicare Advantage Part B and Part D requests carry their own timelines. CMS published a proposed rule on April 14, 2026 at 91 FR 19890 that would extend electronic prior authorization to drugs.

When the drug is administered rather than dispensed. A prescription handed to a patient runs on the pharmacy benefit as an NCPDP claim adjudicated at the point of sale in seconds. The same molecule given in a clinic runs on the medical benefit as a HCPCS J-code on an ASC X12N 837 professional claim, with units, waste and the NDC carried on the line, and payment for most separately payable Part B drugs set at 106 percent of the average sales price. Both are HIPAA adopted standards under 45 CFR 162.1102. Routing a fill to the wrong rail rarely produces a denial you can see. It produces a reimbursement nobody compared with the alternative.

A duplicate discount happens when a covered entity buys a drug at the 340B price and the manufacturer is also asked to pay a Medicaid rebate on the same unit. The statute prohibits it at 42 U.S.C. 256b(a)(5)(A). Avoiding it is an inventory and identification problem rather than a billing problem. The carve-in or carve-out election has to be registered accurately in the HRSA Medicaid Exclusion File, the dispensing record has to show which units came from 340B inventory, and Medicaid claims have to be identified according to the state's own convention. Keep the election, the inventory and the identification consistent and an audit becomes retrieval rather than reconstruction.

By treating it as part of intake rather than as a rescue after a rejection. Copay cards, manufacturer assistance programmes and foundation grants each carry their own eligibility rules, enrolment routes and turnaround times, and none of them move at the speed of a patient at a counter hearing a price for the first time. Assistance is screened when the prescription arrives, alongside benefit verification and prior authorization, so that the financial answer and the clinical answer reach the patient in the same conversation. Fills lost to abandonment are rarely lost on price alone. They are lost on the delay.